PTIX

Protagenic is a development-stage CNS-peptide company with zero product revenue in every year on record (FY2020–FY2024) and a widening loss stream — net loss deepened to -$5.53M in FY2024 from -$5.00M in FY2023, driven by R&D climbing 25.5% to $3.84M. There is no commercial engine here; the entire equity case rests on early, proof-of-concept clinical candidates that management itself says will not generate revenue 'for the foreseeable future.' Five straight years of losses have built a $36.3M accumulated deficit against a stockholders' equity base of just $1.01M, which collapsed 72.4% year-over-year. ROE of -545% is a symptom, not a signal — the equity is almost gone.

The filing makes the risk unambiguous rather than theoretical. The FY2024 10-K carries a going-concern qualification and states cash resources funded operations only 'until the end of the third quarter of 2025' — a runway that, as of today (July 2026), has already lapsed with no fresh financing disclosed in this data. Total assets are $1.96M (down 54.8%) and the last reported cash figure is a stale $671K from FY2020; the company has 'no existing bank lines of credit' and 'no definitive sources for additional financing.' Any survival funding will come via dilution, and the base is already being crushed — shares outstanding jumped 69.7% in FY2024. On top of the balance-sheet stress, the company failed Nasdaq's $1.00 minimum-bid rule, was told in January 2025 it was ineligible for a second cure period, and was operating under a Hearings Panel deadline of April 28, 2025 to demonstrate compliance — a delisting overhang that today's $0.23 price and -36% single-day drop are consistent with.